E
Elena Geuna
Researcher at University of Turin
Publications - 34
Citations - 680
Elena Geuna is an academic researcher from University of Turin. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 11, co-authored 28 publications receiving 533 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant ovarian suppression in premenopausal breast cancer
TL;DR: Patients with low levels of factor XI can safely undergo major orthopedic surgery, a procedure considered to be associated with a high risk of bleeding, and epidemiologic data indicate that patients with congenital factor XI deficiency have a reduced risk of venous thromboembolism.
Journal ArticleDOI
Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions
TL;DR: The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.
Journal ArticleDOI
Metastatic breast cancer subtypes and central nervous system metastases
Caterina Aversa,Valentina A. Rossi,Elena Geuna,Rossella Martinello,Andrea Milani,Stefania Redana,Giorgio Valabrega,Massimo Aglietta,Filippo Montemurro +8 more
TL;DR: In this paper, the authors studied predictors of central nervous system metastases (CNS-M) and outcome after CNS-M diagnosis according to tumor subtype and showed that the Lum/HER2+ subtype appears associated with the longest overall survival.
Journal ArticleDOI
Metastatic breast cancer subtypes and central nervous system metastases.
Caterina Aversa,Elena Geuna,Rossella Martinello,Andrea Milani,Valentina Rossi,Stefania Redana,Giorgio Valabrega,Massimo Aglietta,Filippo Montemurro +8 more
TL;DR: Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic CNS lesions and of more aggressive CNS-M treatment in Lum/HER2+ subtype, which appears associated with the longest OS after central nervous system metastases.
Journal ArticleDOI
Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
Giulia Siravegna,Elena Geuna,Benedetta Mussolin,Giovanni Crisafulli,Alice Bartolini,Danilo Galizia,Laura Casorzo,Ivana Sarotto,Maurizio Scaltriti,Anna Sapino,Alberto Bardelli,Filippo Montemurro +11 more
TL;DR: Analysis of ctDNA in the CSF of HER2-positive mBC is feasible and could represent a useful companion for clinical management of brain metastases, confirming poor treatment benefit in the CNS.